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Abstract Pressure overload (PO) first causes cardiac
hypertrophy and then heart failure (HF), which are
associated with sex differences in cardiac morphology
and function. We aimed to identify genes that may cause
HF-related sex differences. We used a transverse aortic
constriction (TAC) mouse model leading to hypertrophy
without sex differences in cardiac function after 2 weeks,
but with sex differences in hypertrophy 6 and 9 weeks after
TAC. Cardiac gene expression was analyzed 2 weeks after
surgery. Deregulated genes were classified into functional
gene ontology (GO) categories and used for pathway
analysis. Classical marker genes of hypertrophy were
similarly upregulated in both sexes (α-actin, ANP, BNP,
CTGF). Thirty-five genes controlling mitochondrial func-
tion (PGC-1, cytochrome oxidase, carnitine palmitoyl
transferase, acyl-CoA dehydrogenase, pyruvate dehydroge-
nase kinase) had lower expression in males compared to
females after TAC. Genes encoding ribosomal proteins and
genes associated with extracellular matrix remodeling
exhibited relative higher expression in males (collagen 3,
matrix metalloproteinase 2, TIMP2, and TGFβ2, all about
twofold) after TAC. We confirmed 87% of the gene
expression by real-time polymerase chain reaction. By GO
classification, female-specific genes were related to mito-
chondria and metabolism and males to matrix and biosynthe-
sis. Promoter studies confirmed the upregulation ofPGC-1 by
E2. Less downregulation of metabolic genes in female hearts
and increased protein synthesis capacity and deregulation of
matrix remodeling in male hearts characterize the sex-specific
early response to PO. These differences could contribute to
subsequent sex differences in cardiac function and HF.
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Pressure overload (PO), as in hypertension or aortic stenosis,
initially leads to left ventricular hypertrophy (LVH) and later
to heart failure (HF). In the population, women with aortic
stenosis develop less HF at similar mechanical load than
men. HF affects about 10% of persons aged 70 years and
increases thereafter [1–4]. Women more commonly develop
HFwithpreservedejection fraction,whereasmenmoreoften
have HF with reduced ejection fraction [5–7]. In addition,
women with HF have a better outcome at similarly reduced
systolic function [8, 9]. Estrogens improve myocardial
adaptation to PO in hypertensive women [10, 11] and in
mouse models [12, 13]. Several transgenic LVH models
have shown that female animals develop HF and death at a
later time point than males [14–16]. PO in rodent models
leads to LVH with normal systolic function at an early stage
and impaired systolic function at later stages with signifi-
cant sex differences [17–19]. The exact time point when
sex differences appear depends on the model, the degree of
PO, animal age, and strain. In a rat transverse aortic con-
striction (TAC)modelwithmoderatePO,malesshowedmore
LVH and depressed contractile reserve than females [18, 20].
With severe PO, male mice had worse LVH than females by
2w e e k s[ 19]. Gene expression has identified hypertrophy-
related genes mainly in males or in mixed populations [17,
21–23]. The profiles suggested pathways that included
functionally related pro- and antihypertrophy genes or
estrogen receptor (ERα and ERβ)-driven genes [22, 24].
However, only a single microarray study on sex differences
in cardiac hypertrophy has been published so far in mice
[17]. Sex differences that might underlie the functional
differences at later stages were not identified. We aimed to
study this issue and used a novel bioinformatics approach to
define networks of functionally related genes [25, 26].
Materials and methods
Animal experiments
All animal experiments followed the “Principles of laboratory
animal care”(NIH publication No. 86-23, revised 1985) as well
as the current version of the German Law on the Protection of
Animals.
In the first cohort, we randomized 12–14-week-old male
and female C57BL/6J mice to either sham operation or band-
ing of the thoracic aorta [13]. Four animals per group (sham-
operated males, females, TAC males, and females) underwent
echocardiography 2 weeks after surgery and were killed
2 days later. A two-dimensional short-axis view and M-mode
tracings of the left ventricle were obtained with a 45-MHz
transducer (Vevo 770™, VisualSonics, Canada). Wall thick-
ness and left ventricular diameters (LVEDD/LVESD) were
measured according to the American Society for Echocardi-
ography. Left ventricles were immediately frozen in liquid
nitrogen and used for microarray analysis and real-time
polymerase chain reaction (PCR). Hemodynamic parameters
were evaluated in a second cohort of 4×4 male and female
mice that underwent TAC or sham surgery, parallel to the
main experiment. A pressure transducer catheter (Millar
Instruments) was introduced into the right carotid artery and
advanced into the left ventricle to assess ventricular function.
Data were analyzed using a computerized data acquisition
system (Power Lab, ADI Instruments, Melbourne, Australia)
[13]. In a third cohort, echocardiography was done at weeks
2, 6, and 9 after TAC or sham surgery to determine LV mass
(n=62, males/females/sham/TAC).
Microarray analysis
Four individual hearts per group from cohort 1 (sham male,
sham female, TAC male, TAC female) were analyzed on 16
single arrays. The amplification and labeling of the RNA
samples were carried out according to standard protocols
(Affymetrix, Santa Clara, CA, USA). Fifteen micrograms of
each cRNA sample was hybridized to Affymetrix RAE 430A
GeneChip arrays. Arrays were scanned at 3 mm resolution
using the Affymetrix GeneChip System confocal scanner
2500 (Electronic supplementary material), and raw signal
intensities were normalized globally with a scaling factor
using Affymetrix GeneChip® Operating Software (GCOS).
The gene expression data were deposited in the Gene
Expression Omnibus (GEO) database (http://www.ncbi.nlm.
nih.gov/projects/geo/) as GEO accession GSE6970.
Quantification of mRNA by real-time PCR
Total RNA preparation (RNABee, BIOZOL, Germany),
desoxyribonuclease (DNase) digestion (DNAse I, Invitrogen,
Germany), and reverse transcription (SuperScript, Invitrogen,
Germany) were performed according to the manufacturer’s
recommendations. A “hot start” real-time PCR procedure
with SYBR Green was performed in duplicates with the ABI
Prism 7700 Sequence Detection System. The mRNA content
of the target genes was normalized to the expression of
GAPDH in the same sample. Primers for all target genes were
designed using Primer3 Software (Table e1, Electronic sup-
plementary material) [27]. To correct differences in PCR ef-
ficiencies, a calibration curve containing 25, 12.5, 6.25, 3.13,
and 1.56 ng cDNA template pooled from all samples anal-
yzed was run with each primer pair.
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Morphological and functional data were analyzed using the
Mann–Whitney test and one-way analysis of variance
(ANOVA) followed by Tukey’s test. Differences were
considered significant at p<0.05. For the identification of
differentially expressed genes in the comparison of two
conditions with microarrays (male vs. female, TAC vs.
sham), we used the significance analysis of microarrays
(SAM) [28]. The SAM statistic identifies significant
changes in gene expression by performing a set of gene-
specific t tests. For each gene, a score is calculated on the
basis of expression change relative to the standard
deviation of repeated measurements for that gene. Genes
with scores greater than a threshold delta were defined as
significantly deregulated. Manual adjustment of this
threshold delta allows the identification of smaller or larger
gene cohorts. In addition, based on random permutations of
all measurements, a false discovery rate was estimated. For
the identification of differentially expressed genes in the
comparison of four conditions (sham female, sham male,
TAC female, and TAC male) we used a two-way ANOVA
to test for the interaction between hypertrophy (TAC/sham)
and sex (male/female) without correction for multiple
testing. A p value<0.05 indicates that the gene is
deregulated differentially after PO in males and females.
For functional annotation and pathway analysis, we
classified the genes as relatively upregulated in females
or males, respectively. For example, a relative upregulation
in females would correspond to: first, a relative stronger
induction (female TAC/female sham > male TAC/male
sham > 1); second, a weaker repression (1 > female TAC/
female sham > male TAC/male sham); or third, an opposite
regulation (female TAC/female sham > 1 > male TAC/male
sham) of gene expression.
Functional annotation and pathway analysis
For the detection of gene ontology (GO, www.geneontol-
ogy.org) categories and Kyoto Encyclopedia of Genes and
Genomes (KEGG, www.kegg.com)p a t h w a y sw i t ha
significant overrepresentation of genes in a given group
compared to the whole genome, the web-based Database
for Annotation Visualization and Integrated Discovery tool
(DAVID, National Institute of Allergy and Infectious
Disease) was used [25, 26]. Fisher’s exact test was applied
to determine whether or not the proportion of those genes
falling into each GO category or KEGG pathway differed
significantly between the input data set and the whole
genome. Networks of biologically related genes were
created with the help of the Ingenuity Pathways Analysis
(Ingenuity® Systems, www.ingenuity.com). The sex-spe-
cific regulated genes obtained from the microarray
analysis were used to build literature-based sex-specific
networks. In the resulting networks, genes or gene
products are represented as nodes, and the biological rela-
tionship between two nodes is shown as a line. All lines
are supported by at least one reference from literature,
from a textbook, or from canonical information stored in
the Ingenuity Pathways Knowledge Base. For each
network, a score is calculated based on the p value of a
right-tailed Fisher’s exact test. This score calculates the
approximate fit between each network and the focus genes
from the input data set and indicates whether or not a
network contains more genes than expected by chance.
Cell culture and transient transfection reporter assays
Human genomic DNA isolated from peripheral blood
samples of healthy volunteers was used as template to
generate the reporter construct containing the 5′-flanking
region of the PGC-1α gene by PCR with PGC-1α-1.7 kb-
Fw: GATCGGATCCGTGCTGGTGAACTGTATTCAGC,
PGC-1α-0.6 kb-Fw: GATCGGATCCCGCTTTCAAA-
CACTCCCTCAATG, respectively, and PGC-1α-RV:
GATCGGATCCTCCTGAATGACGCCAGTCAAGC pri-
mers. PGC-1α promoter fragments (−1,655 bp/+114 bp
and −515 bp/+114 bp, relative to the transcriptional start
site +1) were cloned into pJET1.2 vector (Fermentas) and
confirmed by sequencing. The individual promoter frag-
ments were subcloned into the luciferase reporter vector
pGL3-basic (Promega) using BglII restriction sites in
sense and antisense orientation. AC16 cells (human
cardiomyocyte cell line, Davidson et al. [29]) were
cultured in phenol red-free DMEM/F12, supplemented
with 12.5% charcoal-stripped fetal calf serum (FCS;
Biochrom AG), penicillin/streptomycin (100 U/ml/
100 μg/ml, PAA), and amphotericin B (0.25 μg/ml) at
37°C under 5% CO2. For transient transfection experi-
m e n t s ,5 0 0n go ft h eP G C - 1 α promoter-luciferase reporter
construct and 100 ng of the internal reference Renilla
luciferase reporter plasmid phRL-TK vector (Promega)
were co-transfected into AC16 cells using FuGENE
® HD
reagent (Roche Diagnostics). In some experiments, ERα-
pSG5 plasmid (HEGO-vector) or its empty vector pSG5
were co-transfected by using a similar transfection
procedure. Twenty-four hours after transfection, cells were
treated with or without E2 (10
−8 M, Sigma) in phenol red-
free DMEM containing 2.5% charcoal-stripped FCS for
additional 24 h. Firefly and Renilla luciferase activities
were measured using the Dual-Glo™ Luciferase Assay
System (Promega). Transfections were carried out in
triplicates for at least three times. The authors had full
access to the data and take responsibility for its integrity.
All authors have read and agreed to the manuscript as
written.
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Sex differences in LVH were present at 6 weeks
but not at 2 weeks
Two weeks after TAC, left ventricular weight to tibia length
(LV/TL) was similarly increased in male and female TAC
animals (males 150±5%; females 144±10%; ns; Fig. 1a).
Echocardiography confirmed that TAC induced a similar
increase in wall thickness in females and males (Fig. 1b).
Heart rate (data not shown), LV pressure, dp/dtmax, and dp/
dtmin were similar in both sexes (Fig. 1c,d). In contrast,
significant sex differences in LV mass were present at week
6a n d9a f t e rT A C( F i g .2).
PO-induced gene regulation
We analyzed the effect of TAC on classical hypertrophy
markers in independent comparisons separately in the two
sexes (TAC female vs. sham female or TAC male vs. sham
male). Eight hundred thirty genes (258 upregulated and 572
downregulated) were responsive to pressure overload in
females and 965 genes (369 upregulated and 596 down-
regulated) in males (false discovery rate <1%, SAM; Fig. 3).
Typical markers of hypertrophy such as alpha skeletal actin,
natriuretic peptide precursor A, natriuretic peptide precursor
B, procollagen type I, and connective tissue growth factor
were induced significantly in both sexes to a similar degree
(Fig. 4a).
Fig. 2 Sex differences at later stages of cardiac hypertrophy. Left
ventricular mass (calculated form echocardiography) to tibia length
(LVM/TL)ratios2 weeks(a), 6 weeks (b), and 9 weeks (c) after surgery
in cohort 3 are shown. Data are presented as mean ± SEM. *p<0.05;
**p<0.001 (one-way ANOVA followed by Tukey’st e s t ) ;S h a m - ma r e
shown in white bars, TAC-m in white bars with black pattern,s h a m - f
are shown in gray bars,a n dT A C - fi ngray bars with black pattern
Fig. 1 Morphology and hemody-
namic measurements. Left ven-
tricular weight to tibia length
(LV/TL; a) ratio, posterior wall
thickness (b), left ventricular sys-
tolic pressure (LVSP; c), and
maximum and minimum rate of
rise of ventricular pressure
(+dp/dtmax and −dp/dtmin (1d))
are shown. In a mean of sham
male (sham-m)m i c ew a ss e ta s
100% and sham female (sham-f)
as well as TAC mice of both
sexes (TAC-m, TAC-f)a r e
expressed as percentage of Sham-
m. Data are presented as mean ±
SEM. *p<0.05; **p<0.001
(Mann–Whitney test); sham-m are
shown in white bars,T A C - mi n
white bars with black pattern,
sham-f are shown in gray bars,
and TAC-f in gray bars with
black pattern
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A small group of genes showed differential expression
between males and females (Fig. 4b, c) independent from
TAC (all males vs. all females). As in previous studies for
somatic tissues [30], the overall number was relatively low
(20 genes, false discovery rate <10%, SAM). Six genes
showed higher expression in females including several X-
linked genes. Fourteen genes showed higher expression in
males including members of the X-degenerated region of
the Y chromosome (Table e2, Electronic supplementary
material).
Fig. 4 Hypertrophy-induced and sex-specific gene expression. mRNA
expression levels of a selection of hypertrophy markers (a)a n da
selection of Y-linked (b) and X-linked (c) genes analyzed by microarray
are shown. The mean mRNA expression level of the 16 individual
samples is set as zero and shown in black for each gene. A relative
upregulation to that mean value is shown in red. The brighter the red
appears the stronger the mRNA expression is upregulated. A relative
downregulation to the mean value is shown in green. The brighter the
green appears the stronger the mRNA expression is downregulated.
False discovery rate (TAC vs. sham) <1% (SAM) false discovery rate
(female vs. male) <10% (SAM)
Fig. 3 Design and statistical
analysis of the microarray
experiments. Four individual
samples for each condition were
hybridized onto Affymetrix RAE
430A GeneChip arrays. The sta-
tistical significance of the influ-
ence of either sex or hypertrophy
(one factor) was calculated using
the significance analysis of
microarrays (SAM). To calculate
sex- and hypertrophy-specific
gene expression (two factors)
ANOVA was used. The set of
deregulated genes (n=653) was
split in a female- and a male-
specific subset which were fur-
ther analyzed with DAVID and
Ingenuity Pathways Analysis
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and confirmatory real-time PCR
TAC-inducedPO led to thedifferentialregulation of 653 genes
in females and males (p<0.05, ANOVA statistics; Table e3,
Electronic supplementary material). Three hundred thirty-
eight genes showed a relative upregulation in females, which
could be due to a relative stronger induction or to a weaker
repression in females or an opposite regulation in both sexes.
These genes are designated female specific. Vice versa, 315
genes showed a relative upregulation in males and are de-
signated male specific. Forty-five genes that differed signif-
icantly in their regulation between both sexes after 2 weeks of
TAC in the microarray analysis (p<0.05, ANOVA) were
selected for confirmation by real-time PCR (Table e4,
Electronic supplementary material). To compare the measure-
ments of the four conditions (sham female, sham male, TAC
female, and TAC male) between the two techniques the
calculated value (female TAC/sham) divided by (male TAC/
sham) was plotted for both approaches (Fig. 5). Relative up-
or downregulation was confirmed in 87% of these genes. For
all genes measured, the relationship of TAC-dependent gene
expression in the two sexes correlated well between the micro-
array analysis and the real-time PCR (p<0.001, r=0.813).
Functional classification of sex-specific regulated genes
The following data analysis steps are based on the two sets of
sex-specific regulated genes: 338 female-specific genes and
315 male-specific genes. These genes were classified accord-
ing to their gene ontology category and presence in KEGG
pathways with the web-accessible DAVID program. The
female-specific genes were significantly overrepresented in
the “biological process” categories of macromolecule metab-
olism, cellular metabolism, and primary metabolism and in the
“cellular component” categories related to mitochondria
(Table e5). The mainly affected KEGG pathways were in-
sulin signaling and propanoate and pyruvate metabolism
(Table 1,T a b l ee6, complete list as Electronic supplementary
material). In contrast, male-specific genes were overrepre-
sented in the “biological process” categories of biosynthesis,
cell organization and biogenesis, and macromolecule metab-
olism (Table 1). Within the category biosynthesis, particularly
a group of 20 ribosomal genes were all relatively stronger and
significantly upregulated in males (Table 2). Accordingly,
male-specificgeneswereoverrepresentedinthe “cellular com-
ponent” category and KEGG pathway ribosome (Table e6,
Electronic supplementary material).
For the identification offunctionally related transcripts, the
two sets of genes with relative overexpression in females or
males were used to build networks with the Ingenuity Path-
ways Analysis software. The most prominent female network
included 29 genes of the import data set and six added ex-
ternal genes (Fig. 6a, Table e7, Electronic supplementary
material). A significant number of these genes were related
to mitochondrial energy metabolism.
The most prominent male network included 32 genes and
three external genes (Fig. 6b, Table e7, Electronic supple-
mentary material). In the male-specific network, genes related
to extracellular matrix synthesis were overrepresented. These
genes included procollagen type III alpha 1 (Col3a1) and pro-
collagen type V alpha 2 (Col5a2), matrix metalloproteinase 2
(MMP2), tissue inhibitor of metalloproteinase 4 (TIMP4),
transcription factors from the sons of mothers against
decapentaplegic (SMAD) family, and transforming growth
factor beta2(TGFβ2).The secondbest male network included
the prohypertrophic transcription factor myocyte enhancer
factor 2C(MEF2;Fig.e1,T a b l ee7, Electronic supplementary
material). MEF2c was downregulated in females, whereas the
gene was almost unchanged in males (ratio female/maleArray=
0.54; ratio female/maleRT-PCR=0.58).
Regulation of the PGC-1α promoter activity by E2
Todetermine the effectofestrogensignaling onthe activityof
the PGC-1α promoter, we co-transfected PGC-1α expression
constructs with or without the ERα plasmid into AC16 cells.
After 24 h of E2 treatment, the relative luciferase activities of
PGC-1α reporter constructs did not change significantly in
responsetoE2aloneinAC16cells,whereasinthepresenceof
ERα plasmid, the transcriptional activation of all PGC-1α
reporter constructs were significantly elevated in response to
E2 (Fig. 7). As negative control, the reporter construct, which
contained PGC-1α 1.7 kb promoter sequence in antisense
Fig. 5 Correlation of the ratios from the microarray and real-time
PCR data set. Genes that differed significantly (p<0.05) in their
regulation by TAC between both sexes in the microarray analysis were
selected based on their biological relevance and were validated with
the same samples by real-time PCR analysis. The ratio (TAC-f/sham-f
divided by TAC-m/sham-m) calculated from the microarray data set
correlated well with the ratio calculated from the real-time PCR data
(r=0.806, p<0.001). A complete list of these genes is shown in
Table e4 (Electronic supplementary material)
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Probe set ID
a Gene title Gene symbol Ratio female vs. male Ratio male vs. female p value
1418112_at Mitochondrial ribosomal protein L10 Mrpl10 0.68 1.47 0.050
1415690_at Mitochondrial ribosomal protein L27 Mrpl27 0.78 1.27 0.015
1424372_at Mitochondrial ribosomal protein L32 Mrpl32 0.77 1.29 0.040
1416984_at Mitochondrial ribosomal protein S18A Mrps18a 0.72 1.38 0.002
1415942_at Ribosomal protein L10 Rpl10 0.80 1.24 0.014
1455485_x_at Ribosomal protein L13a Rpl13a 0.80 1.25 0.020
1437005_a_at Ribosomal protein L18 Rpl18 0.78 1.27 0.003
1455767_x_at Ribosomal protein L21 Rpl21 0.70 1.42 0.005
1415701_x_at Ribosomal protein L23 Rpl23 0.80 1.25 0.023
1437975_a_at Ribosomal protein L23a Rpl23a 0.83 1.21 0.050
1448846_a_at Ribosomal protein L29 Rpl29 0.82 1.22 0.029
1424000_a_at ribosomal protein S11 Rps11 0.81 1.23 0.010
1416088_a_at Ribosomal protein S15 Rps15 0.83 1.21 0.014
1416404_s_at Ribosomal protein S16 Rps16 0.75 1.34 0.027
1428530_x_at Ribosomal protein S24 Rps24 0.76 1.32 0.030
1422475_a_at Ribosomal protein S3a Rps3a 0.86 1.17 0.029
1416054_at Ribosomal protein S5 Rps5 0.76 1.32 0.049
1455364_a_at Ribosomal protein S7 Rps7 0.71 1.41 0.006
1455319_x_at Ribosomal protein S8 Rps8 0.82 1.21 0.031
1449221_a_at Ribosome binding protein 1 Rrbp1 0.42 2.40 0.016
p value indicates interaction of sex and hypertrophy (ANOVA).
aAccession numbers of the microarray set
Table 1 Genes with sex differences in their expression pattern were GO-annotated at level 4 of the categories “biological process” and “cellular
localization” and were sorted in KEGG pathways
Category/pathway No. of genes p value
Ratio >1 (relatively upregulated in females)
Biological process Protein metabolism 81 0.00002348
Cellular macromolecule metabolism 78 0.00002692
Biopolymer metabolism 70 0.00005013
Cellular component Mitochondrion 35 0.00000492
Intracellular membrane-bound organelle 131 0.00001389
Mitochondrial inner membrane 15 0.00016492
KEGG pathway Propanoate metabolism (MMU00640) 4 0.03988610
Pyruvate metabolism (MMU00620) 4 0.05525333
Insulin signaling (MMU04910) 7 0.06556266
Ratio <1 (relatively upregulated in males)
Biological process Macromolecule biosynthesis 38 <0.00000001
Protein metabolism 88 0.00000002
Cellular biosynthesis 44 0.00000002
Cellular component Ribosome 19 0.00000003
Cytosolic ribosome (sensu Eukaryota) 9 0.00000257
Intracellular membrane-bound organelle 140 0.00002176
KEGG pathway Ribosome (MMU03010) 16 0.00000001
Ribosome (HSA03010) 6 0.00026498
Focal adhesion (MMU04510) 12 0.01538544
Categories and pathways showing the highest significance in the overrepresentation of genes are shown. Female-specific genes are significantly
overrepresented in the different categories of metabolism whereas male-specific genes are overrepresented in the categories of biosynthesis.
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These data indicate that the first 600 bp of the PGC-1α
promoter are sufficient to obtain the E2-ERα-mediated effect.
Discussion
We found that many genes were differentially regulated in
male and female mice before sex-specific morphological or
functional changes occurred. We consigned these genes to
networks that feature the predominant early response in the
male and female hearts to PO. Less downregulation of genes
encoding mitochondrial function and fatty acid oxidation
characterized the network of the female hearts and relative
upregulation of matrix remodeling and ribosomal genes the
network of the male hearts. The data support the concept that
better adaptation of energy metabolism in the female hearts,
and greater induction of matrix turnover and ribosomal
protein synthesis in the male hearts, are important mediators
ofsex-dependentremodelingduringearlystagesofPO.These
Fig. 6 Networks of functionally
related genes with a sex-specific
regulation. Ingenuity Pathways
Analysis was used to create
networks derived from the two
sets of genes with a relative
upregulation in females (a)o ri n
males (b; p<0.05, ANOVA sta-
tistics). For each set, the net-
work with the highest score is
shown. Different combinations
of the directions of deregulation
in the comparison of TAC and
sham for males and females
could lead to a sex-specific
expression pattern as indicated
by the color code. Linking
nodes not contained in the two
sets of genes are colored gray.A
number of genes in the female
network (a) are related to energy
metabolism (marked with green
stars). They are grouped around
PGC-1 (PPARGC1A, peroxi-
some proliferative activated re-
ceptor, gamma, coactivator 1,
alpha). In contrasting, many of
the genes in the male network
are related to changes of extra-
cellular matrix (highlighted with
yellow stars) or biosynthesis
(pink stars). The complete list of
genes of the networks can be
seen in Table e7 (Electronic
supplementary material)
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specific functional changes observed at late stages of PO and
LVH.
In transgenic LVH models, HF and death occur earlier in
male than in female animals [14–16, 31]. TAC-induced PO
represents a global stimulus for LVH that is initially con-
centric and leads at later stages to dilatation and HF. Rats
and mice exhibit sex differences in the LVH response to PO
and the transition to HF, which are accompanied by changes
in gene expression [17–20, 32]. However, sex differences in
gene expression that occur after the manifestation of sex
differences in cardiac function may represent a response to
differences in hemodynamic load rather than its cause. We
therefore searched to detect the early sex differences in gene
expression following TAC that may determine the sex dif-
ferences in cardiac function at later stages. We euthanized
mice 2 weeks after TAC to measure gene expression at a time
point when hypertrophy was already present, yet without sex
differences. LVH-related sex differences developed only at
later stages after TAC in our model, similar to other reports
[17–19, 33]. To obtain evidence that our microarray analysis
had sufficient sensitivity and specificity to detect biologically
relevant gene expression changes, we analyzed gene ex-
pression profiles of classical markers of hypertrophy and sex
chromosome-linked genes. Indeed, we observed the upregu-
lation of a comprehensive hypertrophy marker set induced by
TAC as described earlier, as well as Y chromosomal genes in
males [21, 22, 34].
Asignificantoverrepresentationofmale-upregulatedgenes
was found inthe geneontologycategoriesofbiosynthesisand
cell organization, which agrees with published data analyzing
the effects of TAC on gene expression and showing strong
activation of matrix remodeling [21, 22, 34]. A group of
ribosomal genes linked to protein biosynthesis also showed
relative upregulation in male hearts, which may be explained
by the greater need of protein synthesis for increased matrix
turnover. Accordingly, the most prominent male network
assembles matrix regulating genes, namely collagens, matrix
metalloproteinases (MMP), and tissue inhibitors of MMPs
(TIMPs). An increase of MMP14 after PO in males was also
reported earlier in a similar setting [19]. Our data correspond
well to the analyses of PO-induced gene expression in a
similar TAC model by Mirotsou et al. [22]. First, a large
number of hypertrophy-related genes that they found to be
regulated were also detected in our study, including ANP,
collagens, and CTGF. Second, genes with functions related
to cell growth, morphology, differentiation, and ECM activity
were directly correlatedwith LVH, which isalsoinagreement
with our study showing upregulation of matrix-related and
ribosomal genes, predominantly and most pronounced in
males [22]. Based on our findings, male TAC mice have a
higher collagen turnover than females, which may lead to an
altered collagen composition with a different amount of cross
linking and collagen subtypes in both sexes. Indeed, the
modulation of extracellular matrix synthesis has been linked
to sex differences in cardiac stiffness underlying sex differ-
ences in diastolic function in clinical syndromes [6, 17, 20].
Female hearts were characterized by the relatively better
maintenance of metabolic capacity. An unbiased analysis
placed the PPARγ-coactivator 1α (PGC-1) in a central po-
sition in the most relevant female network [35]. PGC-1
stimulates mitochondrial biogenesis and fatty acid oxidation
and reduces glucose oxidation in the myocardium [36, 37].
Accordingly, we found less downregulation of PGC-1-
controlled genes involved in mitochondrial fatty acid metab-
olismandthe respiratorychaininfemales.Examplesincluded
acyl-CoA dehydrogenase, carnitine-palmitoyl transferase,
cytochrome oxidase, and pyruvate dehydrogenase kinase 4,
which downregulates glucose metabolism. Mirotsou et al.
also found an inverse correlation of energy metabolism-
Fig. 7 Effect of E2 and ERα on the transcriptional activity of the
PGC-1α promoter. PGC-1α luciferase reporter constructs were co-
transfected with or without ERα-pSG5 plasmid, along with Renilla
luciferase reporter construct into AC16 cells, and the cells were then
treated with estrogen (E2, 10
−8M) or left untreated. After 24 h, the
luciferase activity was measured and normalized to the Renilla
luciferase activity in each experiment. The graph shows the results
of three independent experiments performed in triplicates, expressed
as mean values ± SEM. **p<0.01 vs. co-transfection without ERα-
pSG5 plasmid
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hypertrophy after TAC in a cohort of females and males,
which was confirmed by our data with the additional finding
of a stronger downregulation in males than in females [22].
Recent work by Wagner et al. in male hearts also showed
that mitochondrial energy metabolism is decreased after
TAC [34]. O’Lone et al. demonstrated that a large number of
energymetabolism-relatedandmitochondrialfunction-related
genes are controlled by estrogen via ERα or ERβ in the
vasculature [24]. This finding corresponds well to the group
of genes that were upregulated in our femalenetwork, namely
genes associated with energy metabolism, mitochondrial
genes, and genes involved in electron transport and fatty acid
oxidation. Interestingly, Haddad et al. found in a gene
expression profiling on idiopathic dilated cardiomyopathy in
humans that metabolic genes are mainly deregulated in
females and genes related to muscular contraction and
extracellular matrix in males [38]. Altogether these studies
indicate that our findings are not restricted to our model, but
represent general mechanisms in the sex-specific adaptation
processes of the heart.
PGC-1 transcription is tightly controlled by the family of
myocyte enhancer factors (MEF) including MEF2c [14].
Mef2c is a transcription factor regulated by the family II of
histone deacetylases (HDAC) and signaling pathways that
utilize calcineurin, calmodulin-dependent protein kinase, and
MAPKs. MEF2c overexpression induces the fetal gene
program and leads to dilated cardiomyopathy [39]. Relative
downregulation of MEF2c in our female mouse hearts may
limit the activation of the hypertrophic gene program fol-
lowing stress and thereby exert protective effects. However,
MEF2c also stimulates mitochondrial biogenesis and func-
tion via upregulation of PGC-1 [14]. Reduction of MEF2c
activity would therefore be expected to lead to a relative
downregulation of PGC-1 and of mitochondrial biosynthesis.
Indeed, in a mouse model with inducible repression of MEF
by permanent HDAC 5 activation, all male mice died within
5–10 days after transgene induction, with highly impaired
mitochondrial structure and function [14]. However, female
mice survived about 30 days with signs of a different patho-
genic process but with normal mitochondrial function. Based
on our data, showing a significant downregulation of MEF2c
but normal PGC-1 expression in hypertrophic female hearts,
we suggest that female mice can maintain PGC-1 indepen-
dent of MEF2c. This capability could allow them to sustain
mitochondrial function in hypertrophic states. This is sup-
ported by our finding of the transcriptional control of the
PGC-1 gene by E2 and with the already documented upre-
gulation of PGC-1 by E2 in vivo, which has protective effects
and restores mitochondrial ATP production, thus preventing
cardiac depression after trauma–hemorrhage [40, 41]. The
unaltered MEF2c gene expression level in banded males and
t h ed e c r e a s ei nb a n d e df e m a l e sm a yt h u sb ei n v o l v e di nt h e
observed morphological and functional sex-dependent
changes at later stages of hypertrophy. The female heart may
maintain an increased cardiac work load under stress by
improved energy supply due to relatively stronger activation
of mitochondrial function and fatty acid oxidation at a lower
degree of activation of a hypertrophic gene profile (Fig. 8).
The upregulation of PGC-1 by estrogen can explain the more
favorable response of the female myocardium to hemody-
namic load and provide a molecular basis for myocardial
protection in female hearts. Endogenous upregulation of
PGC-1 by estrogen is likely to be more favorable than forced
cardiac overexpression of PGC-1 leading to cardiomyopathy
and heart failure [42].
Limitations of the study
Our findings on sex differences in hypertrophy-related gene
expression in mice are consistent with the concepts discussed
in previous reports [17, 19]. Nevertheless, larger assay num-
bers are needed to analyze age dependency and mouse strain
specificity. To describe the pathways involved and to prove
their mediating role, more experimental approaches are re-
quired that alter the function of one or more of the genes
identified.
Species differences between humans and mice have to be
analyzed in further studies as well as the effect of hormonal
status of the females. We found that employing synchronized
females did not reduce inter-animal variability in gene ex-
pression [43]. Finally, to work out the whole complexity of
sex-specific responses in hypertrophy, systems biology, pro-
teomic, and metabolomic approaches must be developed to
complement the expression studies.
Fig. 8 Hypothesis of sex differences in the hypertrophic response to
pressure overload. In female mice, a relative higher expression of
PGC-1 and PDK4 was observed 2 weeks after TAC. This may lead to
a sustained level of fatty acid oxidation and inhibit an increase of
glucose oxidation, indicating an attenuation of the metabolic switch in
the female myocardium after TAC. The relative downregulation of
MEF2c may reduce the hypertrophic gene program and fibrosis
1022 J Mol Med (2008) 86:1013–1024Conclusion
In the early response to pressure overload, a more efficient
metabolic regulation in female hearts, and greater induction
of matrix remodeling in male hearts, may set the stage for
the relative protection of the female hearts. Translation of
these findings to human PO-induced hypertrophy and HF
could benefit both women and men.
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